iNtRON Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

iNtRON Biotechnology has a total shareholder equity of ₩93.0B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩94.8B and ₩1.9B respectively.

Key information

Debt to equity ratio

₩0

Debt

Interest coverage ratio	n/a
Cash	₩56.51b
Equity	₩92.97b
Total liabilities	₩1.88b
Total assets	₩94.85b

Recent financial health updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26

Financial Position Analysis

Short Term Liabilities: A048530's short term assets (₩59.6B) exceed its short term liabilities (₩1.4B).

Long Term Liabilities: A048530's short term assets (₩59.6B) exceed its long term liabilities (₩493.4M).

Debt to Equity History and Analysis

Debt Level: A048530 is debt free.

Reducing Debt: A048530 has no debt compared to 5 years ago when its debt to equity ratio was 25.2%.

Debt Coverage: A048530 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: A048530 has no debt, therefore coverage of interest payments is not a concern.

iNtRON Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Full year 2023 earnings released: ₩292 loss per share (vs ₩168 profit in FY 2022)

Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

iNtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome

Full year 2022 earnings released: EPS: ₩168 (vs ₩288 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

iNtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Price target decreased to ₩16,400

iNtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Develops New CRISPR/Cas Technology Specific for Bacteriophage as PHAGERUS® Platform

iNtRON Biotechnology, Inc. Confirms Efficacy of Cdl200 Against CDI Clinical Isolates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology Completes GLP-TOX Studies of BAL200

Price target decreased to ₩16,400

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology, Inc. announced that it has received KRW 40 billion in funding

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc., Annual General Meeting, Mar 25, 2021

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

New 90-day high: ₩23,000

Investor sentiment improved over the past week

Market bids up stock over the past week

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

New 90-day high: ₩17,050

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

New 90-day low: ₩13,800

New 90-day high - ₩18,100

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies